PMID- 35469781 OWN - NLM STAT- MEDLINE DCOM- 20221026 LR - 20221026 IS - 0003-4509 (Print) IS - 0003-4509 (Linking) VI - 80 IP - 6 DP - 2022 Nov TI - [Prevalence of Adverse Effects of Tyrosine Kinase Inhibitors Used in Management of Chronic Myeloid Leukemia at Sidi Bel-Abbes University Hospital Center]. PG - 932-942 LID - S0003-4509(22)00035-9 [pii] LID - 10.1016/j.pharma.2022.03.004 [doi] AB - INTRODUCTION: Chronic myeloid leukemia (CML) is a malignant hemopathy within the framework of chronic myeloproliferative syndromes, predominant on the granular line. Her drug treatment is based on tyrosine kinase inhibitors (TKIs) which inhibit the abnormal BCR-ABL protein kinase that causes CML and thus block the signals that cause cancer cells to multiply abnormally. However, other proteins are also inhibited, so they can cause a wide range of adverse effects (AEs). The objective of this study was to study the prevalence of AEs of TKIs used in the therapeutic management of CML by the hematology department of University Hospital Center (UHC) of Sidi Bel-Abbes in Algeria and that of the ITK discontinuation following an AE. MATERIALS AND METHODS: It was a retrospective descriptive study carried out over a period of four months, from April 01(st), 2021 to July 31(st), 2021, on CML patients treated with TKI in the hematology department of Sidi Bel-Abbes HUC in Algeria. The primary outcome measure was the prevalence of AEs associated with the use of normal dosages or overdose of the following TKIs: Imatinib, Dasatinib and Nilotinib. Data were collected from patient charts, filled by doctors of hematology department, using questionnaire, and analyzed by Statistical Package for the Social Sciences software, version 20. RESULTS: A total of 40 patients were included, including 22 women, mean age 51.55+/-11.66years (23-78). Twenty-six patients reported at least one AE. Among the 106 AEs declared, 69 AEs (65.09 %) declared with Imatinib, 26 AEs (24.53 %) with Dasatinib and 11 AEs (10.38 %) with Nilotinib. A predominance of musculoskeletal effects 43 (40.56 %), followed by general disorders 18 (17 %), myelosuppression 14 (13.20 %) and digestive system 12 (11.32 %). AEs were responsible for permanent discontinuation of ITK in three cases (11.54 %), including two cases (07.70 %) on Imatinib because of neutropenia and one case (03.84 %) onDasatinibsuffering from pleural effusion. AEs could be controlled in 13 (50 %) of cases, including 9 (34.62%) by temporary discontinuation and 4 (15.38 %) by reducing the dosage, allowing improvement of symptoms and continuation or reintroduction of treatment. CONCLUSION: The prevalence of AEs was high in the studied population, their occurrence was inevitable, good management of AEs from the start of treatment is necessary to avoid switching to another TKI, especially in good responders. It is recommended to establish a low-sodium diet beforehand for all TKIs and a low-carbohydrate diet, especially for Nilotinib, and not to rush to stop the TKI because most often, EIs regress over time in order to allow good therapeutic adherence and obtain better results. CI - Copyright (c) 2022 Academie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved. FAU - Matmour, D AU - Matmour D AD - Laboratoire de Chimie Therapeutique, departement de Pharmacie, faculte de Medecine, universite de Sidi Bel-Abbes, 22000, Algerie; Laboratoire central, centre hospitalo-universitaire AEK Hassani de Sidi Bel-Abbes, 22000, Algerie; Laboratoire de recherche en developpement pharmaceutique, service de pharmacovigilance, faculte de Medecine, EHU 1(er) Novembre, universite d'Oran 1, 31000, Algerie. Electronic address: drmatmour24@hotmail.fr. FAU - Si-Ali, N AU - Si-Ali N AD - Service d'Hematologie, centre Hospitalo-universitaire AEK Hassani de Sidi Bel-Abbes, 22000, Algerie. FAU - Benmehimda, N C AU - Benmehimda NC AD - Laboratoire de Chimie Therapeutique, departement de Pharmacie, faculte de Medecine, universite de Sidi Bel-Abbes, 22000, Algerie; Laboratoire central, centre hospitalo-universitaire AEK Hassani de Sidi Bel-Abbes, 22000, Algerie. FAU - Beloufa, S AU - Beloufa S AD - Laboratoire de Chimie Therapeutique, departement de Pharmacie, faculte de Medecine, universite de Sidi Bel-Abbes, 22000, Algerie; Laboratoire central, centre hospitalo-universitaire AEK Hassani de Sidi Bel-Abbes, 22000, Algerie. FAU - Belfrak, F AU - Belfrak F AD - Laboratoire de Chimie Therapeutique, departement de Pharmacie, faculte de Medecine, universite de Sidi Bel-Abbes, 22000, Algerie; Laboratoire central, centre hospitalo-universitaire AEK Hassani de Sidi Bel-Abbes, 22000, Algerie. FAU - Mahi, E AU - Mahi E AD - Laboratoire de recherche en developpement pharmaceutique, service de pharmacovigilance, faculte de Medecine, EHU 1(er) Novembre, universite d'Oran 1, 31000, Algerie. FAU - Merad, Y AU - Merad Y AD - Laboratoire central, centre hospitalo-universitaire AEK Hassani de Sidi Bel-Abbes, 22000, Algerie. FAU - Toumi, H AU - Toumi H AD - Laboratoire de recherche en developpement pharmaceutique, service de pharmacovigilance, faculte de Medecine, EHU 1(er) Novembre, universite d'Oran 1, 31000, Algerie. FAU - Benlazar, M AU - Benlazar M AD - Service d'Hematologie, centre Hospitalo-universitaire AEK Hassani de Sidi Bel-Abbes, 22000, Algerie. LA - fre PT - English Abstract PT - Journal Article TT - Prevalence des Effets Indesirables des Inhibiteurs de Tyrosine Kinase Utilises dans le Traitement de la Leucemie Myeloide Chronique au CHU de Sidi Bel-Abbes. DEP - 20220422 PL - France TA - Ann Pharm Fr JT - Annales pharmaceutiques francaises JID - 2985176R RN - 0 (Antineoplastic Agents) RN - RBZ1571X5H (Dasatinib) RN - 8A1O1M485B (Imatinib Mesylate) RN - 0 (Protein Kinase Inhibitors) RN - EC 2.7.- (Protein Kinases) SB - IM MH - Adult MH - Female MH - Humans MH - Middle Aged MH - *Antineoplastic Agents/adverse effects MH - Dasatinib/adverse effects MH - Hospitals, University MH - Iatrogenic Disease MH - Imatinib Mesylate/adverse effects MH - *Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy/epidemiology MH - Prevalence MH - Protein Kinase Inhibitors/adverse effects MH - Protein Kinases/therapeutic use MH - Retrospective Studies OTO - NOTNLM OT - Adverse effect OT - Chronic myeloid leukemia OT - Dasatinib OT - Effet indesirable OT - Imatinib OT - Leucemie myeloide chronique OT - Nilotinib OT - Pharmacovigilance EDAT- 2022/04/27 06:00 MHDA- 2022/10/25 06:00 CRDT- 2022/04/26 05:56 PHST- 2021/12/27 00:00 [received] PHST- 2022/03/05 00:00 [revised] PHST- 2022/03/21 00:00 [accepted] PHST- 2022/04/27 06:00 [pubmed] PHST- 2022/10/25 06:00 [medline] PHST- 2022/04/26 05:56 [entrez] AID - S0003-4509(22)00035-9 [pii] AID - 10.1016/j.pharma.2022.03.004 [doi] PST - ppublish SO - Ann Pharm Fr. 2022 Nov;80(6):932-942. doi: 10.1016/j.pharma.2022.03.004. Epub 2022 Apr 22.